Bio-Techne Corp
Research Bio-Techne Corp (TECH) on Bullrun: valuation model: 21.9% overvalued, market cap USD 11.31B, P/E 62.5, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTECH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal21.9% overvalued
- Market capUSD 11.31B
- P/E62.5
- Dividend yield0.4%
- Financial periodFY2026
- RevenueUSD 1.22B
- Revenue growth-0.4%
- Net incomeUSD 181.86M
- Free cash flowUSD 263.22M
- Gross margin65.8%
Valuation Snapshot
Bullrun's latest valuation model marks Bio-Techne Corp as 21.9% overvalued; latest market cap is USD 11.31B; P/E is 62.5; dividend yield is 0.4%.
Peer valuation comparison
Latest P/E is 62.55x versus a Healthcare sector median of 24.64x (153.8% above).
Latest dividend yield is 0.44% versus a Healthcare sector median of 1.83% (75.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 1.22B | USD 181.86M | USD 263.22M | 65.8% | 1.16 | USD 264.71M | USD 289.09M | USD 2.11B |
| FY2025 | USD 1.22B | USD 73.40M | USD 256.55M | 64.8% | 0.46 | USD 162.19M | USD 444.06M | USD 1.92B |
| FY2024 | USD 1.16B | USD 168.11M | USD 236.10M | 66.4% | 1.05 | USD 151.79M | USD 419.54M | USD 2.07B |
| FY2023 | USD 1.14B | USD 285.26M | USD 216.15M | 67.7% | 1.76 | USD 180.57M | USD 454.97M | USD 1.97B |
| FY2022 | USD 1.11B | USD 272.05M | USD 280.36M | 68.4% | 1.66 | USD 172.57M | USD 12.50M | USD 1.70B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 11.31B | 62.5 | 0.4% | 0.32 |
| 2025 | 2025-12-31 | USD 9.17B | 115.3 | 0.5% | 0.32 |
| 2024 | 2024-12-31 | USD 11.37B | 73.5 | 0.4% | 0.32 |
| 2023 | 2023-12-29 | USD 12.20B | 50.8 | 0.4% | 0.32 |
| 2022 | 2022-12-30 | USD 13.01B | 46.3 | 0.4% | 0.32 |
| 2021 | 2021-12-31 | USD 20.34B | 101.0 | 0.2% | 0.32 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.32 USD, yield 0.4%.
| Year | Dividends/share |
|---|---|
| FY2026 | 0.24 USD |
| FY2025 | 0.32 USD |
| FY2024 | 0.32 USD |
| FY2023 | 0.32 USD |
| FY2022 | 0.32 USD |
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
ETFs that hold Bio-Techne Corp
Bio-Techne Corp is one of the ten largest holdings of 9 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| Xtrackers S&P 500 Equal Weight UCITS ETF 1C | 0.26% | 0.15% |
| iShares S&P 500 Equal Weight UCITS ETF USD (Acc) | 0.26% | 0.15% |
| Amundi S&P 500 Equal Weight ESG UCITS ETF Acc | 0.42% | 0.18% |
| Invesco S&P 500 Equal Weight Index ETF Acc | 0.26% | 0.20% |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR Hedged | 0.26% | 0.30% |
| Global X Genomics & Biotechnology UCITS ETF USD Acc | 3.66% | 0.50% |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2D | 0.26% | 0.15% |
| Invesco S&P 500 Equal Weight Index ETF Inc | 0.26% | 0.20% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Bio-Techne Corp overvalued or undervalued?
Bullrun's valuation model currently marks Bio-Techne Corp as 21.9% overvalued.
What is Bio-Techne Corp's market cap?
Bio-Techne Corp's market capitalization is USD 11.31B.
What is Bio-Techne Corp's P/E ratio?
Bio-Techne Corp's price-to-earnings (P/E) ratio is 62.5.
Does Bio-Techne Corp pay a dividend?
Bio-Techne Corp has a dividend yield of 0.4%.
What does Bio-Techne Corp do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.